Skip to Content

Generic Pristiq Availability

Pristiq is a brand name of desvenlafaxine, approved by the FDA in the following formulation(s):

PRISTIQ (desvenlafaxine succinate - tablet, extended release;oral)

  • Manufacturer: WYETH PHARMS INC
    Approval date: February 29, 2008
    Strength(s): EQ 50MG BASE [RLD], EQ 100MG BASE [RLD]
  • Manufacturer: WYETH PHARMS INC
    Approval date: August 20, 2014
    Strength(s): EQ 25MG BASE

Has a generic version of Pristiq been approved?

No. There is currently no therapeutically equivalent version of Pristiq available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pristiq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Succinate salt of O-desmethyl-venlafaxine
    Patent 6,673,838
    Issued: January 6, 2004
    Inventor(s): Anthony F.; Hadfield & Syed M.; Shah & Michael W.; Winkley & Karen W.; Sutherland & James A.; Provost & Aeri; Park & Rex A.; Shipplett & Brenton W.; Russell & Beat T.; Weber
    Assignee(s): Wyeth
    A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.
    Patent expiration dates:
    • March 1, 2022
      Drug substance
    • March 1, 2022
      Drug substance
  • Derivatives of venlafaxine and methods of preparing and using the same
    Patent 8,269,040
    Issued: September 18, 2012
    Inventor(s): Jerussi; Thomas P. & Senanayake; Chrisantha H. & Bhongle; Nandkumar N.
    Assignee(s): Wyeth LLC
    Methods of preparing, and compositions comprising, derivatives of venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.
    Patent expiration dates:
    • July 5, 2027
      Drug substance

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.